Navigation Links
LSUSHC research identifies new experimental drug for stroke
Date:2/29/2012

New Orleans, LA Research led by Nicolas Bazan, MD, PhD, Boyd Professor and Director of the Neuroscience Center of Excellence at LSU Health Sciences Center New Orleans, has found that a synthetic molecule protected the brain in a model of experimental stroke. Dr. Bazan was issued a patent on the molecule called LAU-0901, a low molecular weight drug that crosses the blood-brain barrier. The findings are published in the March 2012 issue of Translational Stroke Research.

During an ischemic stroke, the most common kind, the body releases signals that cause neuroinflammation which leads to a buildup of chemicals that harm the brain. Platelet-activating factor (PAF) accumulates, and inhibition of this process plays a critical role in neuronal survival.

"LAU-0901 is able to reduce this incorrect signaling and inhibit the PAF receptor, which reduces multiple neuroinflammatory signals and greatly lessens the severity of damage in experimental stroke," notes Dr. Bazan.

The research team used magnetic resonance imaging in conjunction with behavior and immunohistopathology to further study this novel therapeutic approach. The researchers report that LAU-0901, given two hours after the onset of experimental stroke, lessened the severity of brain damage, significantly reduced lesions in the brain, and improved coordination and movement. LAU-0901 produced no discernible side effects. These findings suggest LAU-0901 is a promising neuroprotectant that provides the basis for future therapeutics in patients suffering ischemic stroke.

Stroke is a leading cause of death and disability worldwide. Conventional therapies for ischemic stroke include thrombolytic therapy, prevention of inappropriate coagulation and thrombosis, and surgery to repair vascular abnormalities.Only one FDA-approved therapy exists for treatment of acute ischemic stroke, the thrombolytic tissue plasminogen activator (tPA), but only 5𔃆% of all ischemic stroke patients are eligible for treatment with tPA.

The research team also included Professor Ludmila Belayev and MD/PhD student Tiffany Niemoller Eady at LSU Health Sciences Center New Orleans, as well as Dr. Julio Alvarez Builla and other scientists from the University of Alcala, Spain, and Dr. Andre Obenaus at the University of Loma Linda.


'/>"/>

Contact: Leslie Capo
lcapo@lsuhsc.edu
504-568-4806
Louisiana State University Health Sciences Center
Source:Eurekalert

Related biology news :

1. LSUSHC researchers find potential new target for hypertension treatment
2. Wistar Institute researcher receives New Innovator award from NIH
3. NC State researchers get to root of parasite genome
4. White Mountain Research Station to host climate change conference
5. Stevens awarded $1M for advanced biofuels research
6. Researchers find animal with ability to survive climate change
7. Researchers find an essential gene for forming ears of corn
8. Researchers note differences between people and animals on calorie restriction
9. Researcher working on destruction of chemical weapons
10. Researchers study acoustic communication in deep-sea fish
11. Researchers discover that growing up too fast may mean dying young in honey bees
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. ... has priced an offering of €500.0 million principal amount of ... principal amount of its 2.425% senior unsecured notes due 2026. ... to occur on December 13, 2016, subject to the satisfaction of ... annual basis. The Company intends ...
(Date:12/6/2016)... DALLAS , Dec. 6, 2016 ... criminal justice technology solutions for public safety, investigation, ... (PEP) jointly announced today a five (5) year ... exclusive agreement to expand the rehabilitation and reentry ... PEP History Established in 2004, the Prison ...
(Date:12/2/2016)... , December 1, 2016 ... (Fingerprint, Voice), Future Technology (Iris Recognition System), Vehicle ... - Global Forecast to 2021", published by MarketsandMarkets, ... Million in 2016, and is projected to grow ... CAGR of 14.06%.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016 Soligenix, Inc. (OTCQB: ... focused on developing and commercializing products to treat rare ... today that it will be hosting an Investor Webcast ... on the origins of innate defense regulators (IDRs) as ... of oral mucositis and the recently announced and published ...
(Date:12/8/2016)... Dec. 8, 2016 Eutilex Co. Ltd. today ... (US $18.9M) Series A financing. This financing round included ... Venture and SNU Bio Angel. This new funding brings ... KRW (US $27.7M) since its founding in 2015. ... the development and commercialization of its immuno-oncology programs, expand ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... its phase I/II dose escalation and expansion clinical trial for its lead drug ... Austria. The purpose of the trial was to determine the safety, antitumor activity, ...
(Date:12/7/2016)... 2016 Neogen Corporation (NASDAQ: NEOG ... Kephart as its chief science officer — a ... responsibilities at Neogen effective Jan. 1. Kephart ... agribusiness unit of Thermo Fisher Scientific, as well as ... His extensive industry experience also includes the management of ...
Breaking Biology Technology: